Patents by Inventor CUNFA LI

CUNFA LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12390503
    Abstract: The present disclosure provides a ginkgo biloba ketone ester capsule. The present disclosure further provides a method for preparing ginkgo biloba ketone ester capsule and use thereof. The present disclosure provides a ginkgo biloba ketone ester capsule and a preparation method thereof. Through optimized preparation operations and conditions, a high-quality ginkgo biloba ketone ester capsule can be obtained. Compared with the ginkgo biloba ketone ester capsule prepared by traditional methods, the ginkgo biloba ketone ester capsule of the present disclosure has stable quality and a low unqualified rate. The consistency of different batches of ginkgo biloba ketone ester capsules is good. In particular, the ginkgo biloba ketone ester capsule can effectively control ginkgolic acids, preventing the use of high-ginkgolic-acid raw materials in the ginkgo biloba ketone ester capsules, so as to effectively improve the safety of ginkgo biloba ketone ester capsules.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: August 19, 2025
    Assignee: SPH XING LING SCI. & TECH. PHARMACEUTICAL CO., LTD.
    Inventors: Dandan Wang, Qi Gao, Jun Wang, Baozhong Zhu, Cunfa Li, Xueyi Zhang, Yafang Wei
  • Publication number: 20250082703
    Abstract: A ginkgo biloba ketone ester capsule is provided, which is prepared by mixing ginkgo biloba ketone ester raw materials and excipients, granulating and filling into capsules. The ginkgo biloba ketone ester capsule, based on a loading weight of each capsule being 0.2 g, meets the following conditions: 1) a content of rutin is less than or equal to 1.60 mg/capsule; 2) a content of quercetin is less than or equal to 0.160 mg/capsule; 3) a content of bilobalide is 1.04-2.08 mg/capsule; 4) a content of ginkgolide J is 0.04-0.20 mg/capsule; 5) a residual content of ethanol is less than or equal to 0.2 mg/capsule; 6) a content of biflavonoids is less than or equal to 0.008 mg/capsule, the biflavonoids include Amentoflavone, Bilobetin, and Ginkgetin; and 7) a content of Genistin is 0, and a content of ginkgolide M is 0.
    Type: Application
    Filed: September 19, 2024
    Publication date: March 13, 2025
    Applicant: SPH Xing Ling Sci. & Tech. Pharmaceutical Co., Ltd.
    Inventors: Dandan WANG, Qi GAO, Jun WANG, Baozhong ZHU, Cunfa LI, Xueyi ZHANG, Yafang WEI
  • Publication number: 20220080005
    Abstract: The present disclosure provides a ginkgo biloba ketone ester capsule. The present disclosure further provides a method for preparing ginkgo biloba ketone ester capsule and use thereof. The present disclosure provides a ginkgo biloba ketone ester capsule and a preparation method thereof. Through optimized preparation operations and conditions, a high-quality ginkgo biloba ketone ester capsule can be obtained. Compared with the ginkgo biloba ketone ester capsule prepared by traditional methods, the ginkgo biloba ketone ester capsule of the present disclosure has stable quality and a low unqualified rate. The consistency of different batches of ginkgo biloba ketone ester capsules is good. In particular, the ginkgo biloba ketone ester capsule can effectively control ginkgolic acids, preventing the use of high-ginkgolic-acid raw materials in the ginkgo biloba ketone ester capsules, so as to effectively improve the safety of ginkgo biloba ketone ester capsules.
    Type: Application
    Filed: September 12, 2018
    Publication date: March 17, 2022
    Applicant: SPH XING LING SCI. & TECH. PHARMACEUTICAL CO., LTD.
    Inventors: DANDAN WANG, QI GAO, JUN WANG, BAOZHONG ZHU, CUNFA LI, XUEYI ZHANG, YAFANG WEI